Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Cerevance Closes $51 M with Series B Expansion

2023-02-13
BOSTON, MA, Cerevance, a private, clinical-stage drug discovery and development company
expands Series B funding round with an additional close of $51 million.
Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company's proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced an expansion of its Series B funding round with an additional close of $51 million, bringing the total Series B financing to $116 million. The financing will support upcoming clinical trials focused on Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors